Rivaroxaban is a Small Molecule owned by Bayer, and is involved in 196 clinical trials, of which 163 were completed, 30 are ongoing, and 3 are planned.

Rivaroxaban is a factor Xa inhibitor. The drug candidate blocks factor Xa, an enzyme that is involved in the production of thrombin. Thrombin is central to the process of blood clotting. The activated Factor X (Factor Xa) is a central component of the prothrombinase complex, which converts large amounts of prothrombin (Factor II) to thrombin, described as the “thrombin burst”. By blocking factor Xa, the levels of thrombin decrease, which reduces the risk of blood clots forming in the veins and arteries, and also treats existing clots.

The revenue for Rivaroxaban is expected to reach a total of $9.1bn through 2030. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Rivaroxaban NPV Report.

Rivaroxaban is originated and owned by Bayer. Johnson & Johnson is the other company associated in development or marketing of Rivaroxaban.

Rivaroxaban Overview

Rivaroxaban (Xarelto) belongs to the class of antithrombotic agents. It is formulated as film-coated tablets, tablets, granules/powder for suspension and suspension for oral route of administration. Xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery. Rivaroxaban is indicated for the treatment of adults, to prevent venous thromboembolism (VTE, the formation of clots in the veins) in patients who are undergoing surgery to replace a hip or knee; to prevent stroke caused by a blood clot in the brain and systemic embolism (a blood clot in a blood vessel) in patients with non-valvular atrial fibrillation (irregular rapid contractions of the upper chambers of the heart); and to treat deep vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg), and to prevent DVT re-occurring and pulmonary embolism (a clot in a blood vessel supplying the lungs) following a severe case of DVT. Xarelto is also indicated for the treatment of pulmonary thromboembolism and deep vein thrombosis. Xarelto film-coated tablet (2.5 mg), in combination with 75 mg -100 mg acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with symptomatic peripheral artery disease (PAD) at demonstrated high risk of major adverse limb events (MALE) or major adverse cardiovascular and cerebrovascular events (MACCE). Xarelto is indicated for thromboprophylaxis in pediatric patients aged 2 years and older with congenital heart disease who have undergone the Fontan procedure, venous thromboembolism (VTE) and the reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant treatment.

Rivaroxaban (Xarelto) is under development for the treatment of acute venous thromboembolism in pediatric and adult patients, coronary artery disease and high risk of thromboembolic disease in moderate to severe coronavirus disease 2019 (COVID-19).

It was also under development for the prevention of major adverse cardiac events (MACE) in patients with chronic heart failure and significant coronary artery disease, heparin-induced thrombocytopenia (HIT), prevention of stroke in patients who have experienced embolic stroke of undetermined source (ESUS) and myocardial infarction.

Johnson & Johnson Overview

Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

The company reported revenues of (US Dollars) US$93,775 million for the fiscal year ended January 2021 (FY2021), an increase of 13.6% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 20% in FY2020. In FY2021, the company recorded a net margin of 22.3%, compared to a net margin of 17.8% in FY2020. The company reported revenues of US$23,791 million for the third quarter ended October 2022, a decrease of 1% over the previous quarter.

Quick View – Rivaroxaban

Report Segments
  • Innovator (NME)
Drug Name
  • Rivaroxaban
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Hematological Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.